Nicola J Lawrence, Bobbi B Laing, Joseph Tyro, Scott Babington, Marina Dzhelali, Adele Gautier, Dixon Grant, Prashanth Hari Dass, Michael Jameson, Carolyn Lauren, Jessica Maxwell, Ngapei Ngatai, Rix du Plessis, Charlie Stratton, Alvin Tan, Madison Williams, Michelle Wilson
{"title":"Process of development of decentralised clinical trial methodology for cancer clinical trials in Aotearoa New Zealand.","authors":"Nicola J Lawrence, Bobbi B Laing, Joseph Tyro, Scott Babington, Marina Dzhelali, Adele Gautier, Dixon Grant, Prashanth Hari Dass, Michael Jameson, Carolyn Lauren, Jessica Maxwell, Ngapei Ngatai, Rix du Plessis, Charlie Stratton, Alvin Tan, Madison Williams, Michelle Wilson","doi":"10.26635/6965.6628","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To develop processes for the development of decentralised clinical trial methodology for Aotearoa New Zealand, focussing on equity of access to cancer clinical trials for Māori, Pacific people, vulnerable communities and those in rural settings.</p><p><strong>Methods: </strong>A national steering committee supported by Te Aho o Te Kahu - Cancer Control Agency was formed to: guide the adaptation and implementation of overseas decentralised clinical trial models to suit the needs of Aotearoa New Zealand with an equity focus; provide high-level oversight and expertise for direction and development of policies, procedures and infrastructure compliant with ICH GCP R2; and implement a national strategy.</p><p><strong>Results: </strong>Twelve standard operating procedures were developed, as well as a supervision plan and a glossary. These were made freely available on the New Zealand Association of Clinical Research website.</p><p><strong>Conclusion: </strong>Decentralised clinical trials offer a novel method of trial conduct that is patient- and whānau-centred. The model allows patients to remain in their local area with whānau and support networks, and their local treating team, increasing clinical trial accessibility and quality of care. This methodology has the potential to support improvement in research capabilities nationally and be utilised beyond oncology. It would benefit from significant investment in national clinical trial infrastructure.</p>","PeriodicalId":48086,"journal":{"name":"NEW ZEALAND MEDICAL JOURNAL","volume":"137 1607","pages":"12-21"},"PeriodicalIF":1.2000,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NEW ZEALAND MEDICAL JOURNAL","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26635/6965.6628","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: To develop processes for the development of decentralised clinical trial methodology for Aotearoa New Zealand, focussing on equity of access to cancer clinical trials for Māori, Pacific people, vulnerable communities and those in rural settings.
Methods: A national steering committee supported by Te Aho o Te Kahu - Cancer Control Agency was formed to: guide the adaptation and implementation of overseas decentralised clinical trial models to suit the needs of Aotearoa New Zealand with an equity focus; provide high-level oversight and expertise for direction and development of policies, procedures and infrastructure compliant with ICH GCP R2; and implement a national strategy.
Results: Twelve standard operating procedures were developed, as well as a supervision plan and a glossary. These were made freely available on the New Zealand Association of Clinical Research website.
Conclusion: Decentralised clinical trials offer a novel method of trial conduct that is patient- and whānau-centred. The model allows patients to remain in their local area with whānau and support networks, and their local treating team, increasing clinical trial accessibility and quality of care. This methodology has the potential to support improvement in research capabilities nationally and be utilised beyond oncology. It would benefit from significant investment in national clinical trial infrastructure.
目的:为新西兰奥特亚罗瓦地区制定分散临床试验方法,重点关注毛利人、太平洋岛屿居民、弱势社区和农村地区居民公平获得癌症临床试验的问题:在 Te Aho o Te Kahu(癌症控制机构)的支持下,成立了一个国家指导委员会,负责:指导海外分散临床试验模式的调整和实施,以适应新西兰奥特亚罗瓦地区的需求,并注重公平;提供高层次的监督和专业知识,指导和制定符合 ICH GCP R2 的政策、程序和基础设施;实施国家战略:结果:制定了 12 项标准操作程序以及监督计划和词汇表。这些都可在新西兰临床研究协会的网站上免费获取:分散临床试验提供了一种以患者和家庭为中心的新型试验方法。这种模式允许患者留在当地,与当地人和支持网络以及当地治疗团队在一起,提高了临床试验的可及性和护理质量。这种方法有可能支持提高全国的研究能力,并在肿瘤学以外的领域得到应用。它将受益于国家临床试验基础设施的重大投资。